1. |
Obst W, von Arnim U, Malfertheiner P. Whipple’s disease. Viszeralmedizin, 2014, 30(3): 167-172.
|
2. |
Lagier JC, Lepidi H, Raoult D, et al. Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore), 2010, 89(5): 337-345.
|
3. |
Wang S, Xia D, Wu J, et al. Severe pneumonia caused by infection with Tropheryma whipplei complicated with Acinetobacter baumannii infection: a case report involving a young womane. Front Public Health, 2021, 9: 729595.
|
4. |
徐克, 龚启勇, 韩萍, 等. 医学影像学. 8 版. 北京: 人民卫生出版社, 2018.
|
5. |
Rusina R, Keller O, Síma R, et al. Peripheral neuropathy in Whipples disease: a case report. Cesk Patol, 2012, 48(2): 97-99.
|
6. |
Edouard S, Fenollar F, Raoult D. The rise of Tropheryma whipplei: a 12-year retrospective study of PCR diagnoses in our reference center. J Clin Microbiol, 2012, 50(12): 3917-3920.
|
7. |
Schnider PJ, Reisinger EC, Gerschlager W, et al. Long-term follow-up in cerebral Whipple’s disease. Eur J Gastroenterol Hepatol, 1996, 8(9): 899-903.
|
8. |
Fenollar F, Mediannikov O, Socolovschi C, et al. Tropheryma whipplei bacteremia during fever in rural West Africa. Clin Infect Dis, 2010, 51(5): 515-521.
|
9. |
Duss FR, Jaton K, Vollenweider P, et al. Whipple disease: a 15-year etrospective study on 36 patients with positive polymerase chain reaction for Tropheryma whipplei. Clin Microbiol Infect, 2021, 27(6): 910.e9-910.e13.
|
10. |
Bousbia S, Papazian L, Auffray JP, et al. Tropheryma whipplei in patients with pneumonia. Emerg Infect Dis, 2010, 16(2): 258-263.
|
11. |
Martinetti M, Biagi F, Badulli C, et al. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple’s disease. Gastroenterology, 2009, 136(7): 2289-2294.
|
12. |
Lozupone C, Cota-Gomez A, Palmer BE, et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med, 2013, 187(10): 1110-1117.
|
13. |
Marth T. Systematic review: Whipple’s disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors. Aliment Pharmacol Ther, 2015, 41(8): 709-724.
|
14. |
El-Abassi R, Soliman MY, Williams F, et al. Whipple’s disease. J Neurol Sci, 2017, 377: 197-206.
|
15. |
Hujoel IA, Johnson DH, Lebwohl B, et al. Tropheryma whipplei infection (Whipple disease) in the USA. Dig Dis Sci, 2019, 64(1): 213-223.
|
16. |
Schwartzman S, Schwartzman M. Whipple’s disease. Rheum Dis Clin North Am, 2013, 39(2): 313-321.
|
17. |
Compain C, Sacre K, Puéchal X, et al. Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine (Baltimore), 2013, 92(6): 324-330.
|
18. |
Lin M, Wang K, Qiu L, et al. Tropheryma whipplei detection by metagenomic next-generation sequencing in bronchoalveolar lavage fluid: a cross-sectional study. Front Cell Infect Microbiol, 2022, 12: 961297.
|
19. |
李会东, 邢柏. 乳酸脱氢酶对感染性休克患者预后的评估价值. 中国急救医学, 2019, 39(3): 211-215.
|
20. |
Dolmans RA, Boel CH, Lacle MM, et al. Clinical manifestations, treatment, and diagnosis of Tropheryma whipplei infections. Clin Microbiol Rev, 2017, 30(2): 529-555.
|
21. |
Masselot F, Boulos A, Maurin M, et al. Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm. Antimicrob Agents Chemother, 2003, 47(5): 1658-1664.
|
22. |
Fenollar F, Perreal C, Raoult D. Tropheryma whipplei natural resistance to trimethoprim and sulphonamides in vitro. Int J Antimicrob Agents, 2014, 43(4): 388-390.
|
23. |
Lagier JC, Fenollar F, Lepidi H, et al. Treatment of classic Whipple’s disease: from in vitro results to clinical outcome. J Antimicrob Chemother, 2014, 69(1): 219-227.
|